ecrin-mdr-crcClinical2009IPD Sharing (as of September 2022): Yes Description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized, and study documents will be redacted to protect the privacy of study participants. Any requests should be submitted to www.vivli.org for assessment by an independent scientific review board. Time frame: Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and EU or after the primary manuscript describing the results has been accepted for publication, whichever is later. Access Criteria: Further details on Ipsen’s sharing criteria, eligible studies and process for sharing are available here (https://vivli.org/members/ourmembers/). URL: https://vivli.org/members/ourmembers/Malignant Carcinoid SyndromeFlushingCarcinoid TumorDiarrhoeaCarcinoid SyndromeSerotonin SyndromeMalignant Carcinoid SyndromeFlushingCarcinoid TumorDiarrhoeaCarcinoid SyndromeSerotonin SyndromeInterventionalhttps://newmdr.ecrin.org/Study/2062737LatviaTurkeyUnited StatesCzechiaUkraineBrazilPolandSouth AfricaSerbiaCroatiaIndiaRussia5Neuroendocrine tumourLanreotideCarcinoid tumourDiarrheaSomatuline DepotLanreotide AutogelSomatostatinNETNeuroendocrine tumorLanreotide Autogel 120mgECRIN MDRCompletedfalseAn Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid SyndromeThe purpose of this study was to determine whether monthly deep subcutaneous (s.c.) injections of lanreotide Autogel (Somatuline Depot) were effective and safe in controlling diarrhoea and flushing by reducing the usage of s.c. short-acting octreotide as a rescue medication to control symptoms in subjects with carcinoid syndrome.2009-05-152062737NCT007749302010-019066-92